IMUNON, Inc. reported a net loss of $4.3 million in Q1 2026 while advancing its Phase 3 OVATION 3 trial for IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. The Phase 2 trial showed a median overall survival improvement of 14.7 months, with even greater benefit when combined with PARP inhibitors. The FDA has aligned with the Phase 3 protocol, supporting a path to Biologics License Application (BLA) filing. Enrollment in the pivotal Phase 3 study is on track to complete by Q1 2029, positioning IMNN-001 as a potential new standard of care for ovarian cancer.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
